Product Name: TAK1 (436-442) pS439
Product Number: PE-04APV90
| Size: | 200 µg | Price: | 37.00 | |
| 1 mg | $US | 74.00 | ||
| 5 mg | 174.00 |
Peptide Name: TAK1 (436-442) pS439
Product Use: Services as a blocking peptide for use with the TAK1-pS439 rabbit polyclonal antibody (Cat. No.: AB-PK824) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminal half of the protein. This is the major in vivo phosphorylation site in TAK1. The effect of its phosphorylation is unclear.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: RRR-pS-IQD
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Product Use: Services as a blocking peptide for use with the TAK1-pS439 rabbit polyclonal antibody (Cat. No.: AB-PK824) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminal half of the protein. This is the major in vivo phosphorylation site in TAK1. The effect of its phosphorylation is unclear.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: RRR-pS-IQD
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1183.24 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: TAK1 - pS439 phosphosite-specific antibody (Cat. No.: AB-PK824)
Peptide Molecular Mass Calculated: 1183.24 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: TAK1 - pS439 phosphosite-specific antibody (Cat. No.: AB-PK824)
Scientific Background: TAK1 (MAP3K7, MEKK7) is a protein-serine/threonine kinase of the TKL group and MLK family. TAK1 is activated by proinflammatory cytokines and in response to physical/chemical stress, including UVR, osmotic- and oxidative stress. It is a mediator of TRAF6 and TGF-beta signal transduction, and activates IKBKB and MAPK8 in response to TRAF6 signalling. It also stimulates NF?B activation and activation of the p38 MAPK (MAPK8) pathway. It is responsible for controlling a variety of cell functions such as transcription and apoptosis. It regulates hepatic cell survival and carcinogenesis. TAK1 is important for TGF-beta1 regulation of MMP9 and the metastatic potential of certain breast cancer cell lines. It is activated by phosphorylation at T178, T184, T187 and S192. It is also activated by K63-linked polyubiquitination. TAK1 plays a role in tumour initiation, progression, and metastasis such as in breast cancer as a tumour inducer or tumour suppression depending on the cancer.
© Kinexus Bioinformatics Corporation 2017